Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea

• Liminatus Pharma engaged Korea-based Synex Consulting as CRO to support Phase 1/2a development of IBC101 CD19xCD22 bivalent CAR-T.
• Work targets clinical execution in South Korea following MFDS authorization for a relapsed or refractory DLBCL study.
• Seoul St. Mary’s Hospital named lead site for the Phase 1/2a trial.
• Contract uses milestone-based payments tied to patient enrollment, database lock, and completion of the clinical study report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240800PRIMZONEFULLFEED9814403) on August 24, 2026, and is solely responsible for the information contained therein.